The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...
Taysha Gene Therapies shares fall after regaining full rights to Rett syndrome drug TSHA-102 and finalizing FDA alignment for ...
Taysha’s TSHA-102 shows 100% response in Rett, with FDA Breakthrough status and strong trial design supporting BLA hopes.
(RTTNews) - Biotechnology company Taysha Gene Therapies, Inc. (TSHA) announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to TSHA-102, an intrathecally ...
JCR presented non-clinical data that demonstrate the ability of its proprietary JUST-AAV platform to achieve efficient ...
Taysha Gene Therapies' investigational treatment for Rett syndrome has received breakthrough-therapy designation from the Food and Drug Administration.
Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...
Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from ...
The AAV gene therapy market size is calculated at USD 3.85 billion in 2025 and is expected to reach around USD 78.56 billion by 2034, growing at a CAGR of 40.1% for the forecasted period.Ottawa, Oct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback